|Bid||0.00 x 800|
|Ask||0.00 x 1800|
|Day's Range||14.63 - 15.01|
|52 Week Range||5.61 - 25.10|
|Beta (3Y Monthly)||2.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it has entered into an agreement to acquire an 84,000 square foot GMP compliant fermentation and manufacturing facility in Winnipeg, Canada from Apotex Fermentation Inc. (“AFI”). As previously announced, Cronos Group has entered into a partnership with Ginkgo Bioworks, Inc. (“Ginkgo”) to produce cultured cannabinoids.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that Dr. Todd Abraham has been appointed as the Company’s Chief Innovation Officer. In this role, Dr. Abraham will be responsible for advancing Cronos Group’s research and development initiatives in cannabinoids with a focus on identifying new disruptive technologies and adopting best practices and innovations from adjacent consumer goods industries.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), will announce its financial results for the second quarter ended June 30, 2019, and hold its Second Quarter 2019 Earnings Conference Call on Thursday, August 8, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) reports that at its Annual Meeting of Shareholders on June 19, 2019 there were 610 shareholders voting in person or by proxy holding in total 261,290,314 common shares, representing 78.2% of the total number of common shares outstanding.
Cronos Group Inc. (“Cronos Group” or the “Company”) (CRON.TO) (CRON.TO), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer, will speak at three industry conferences in June. Mr. Gorenstein will present at the Piper Jaffray 39th Annual Consumer Marketplace Conference on Thursday June 6, 2019 at 1:30 p.m. ET in New York, NY, the Jefferies 2019 Healthcare Conference on Friday June 7, 2019 at 11:30 a.m. ET in New York, NY and the Stifel 2019 Cross Sector Insight Conference on Wednesday June 12, 2019 at 1:15 p.m. ET in Boston, MA. The presentations will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, will hold its 2019 Annual Meeting of Shareholders on Wednesday, June 19, 2019 at 10 a.m. ET at the offices of Blake, Cassels & Graydon LLP located at 199 Bay Street, Suite 4000, Commerce Court West, Toronto. The Notice of Meeting and Management Information Circular are available on the Governance section of the Company’s website at https://ir.thecronosgroup.com/investor-relations. A live audio webcast and replay of the meeting will also be available in the Investor Relations section of the Company’s website.
MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months. In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.
Cronos Group Closes C$2.4 Billion Strategic Investment from Altria Group Cronos Group Establishes Cronos Device Labs, a State-of-the-Art Vaporizer R&D Initiative NatuEra.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it is expanding its global infrastructure network and innovation capabilities with the opening of a cannabinoid device R&D facility, based in Israel (“Cronos Device Labs”). The state-of-the-art facility supports Cronos Group’s efforts to develop next-generation vaporizer products that are designed specifically for cannabinoid applications. Cronos Device Labs, which is equipped with an experienced team of product development talent, advanced vaporizer technology and analytical testing infrastructure, serves as the global center of R&D for the Company’s vaporizer devices.
One company we've highlighted in the past CleanSpark, Inc. (CLSK) has developed power solution for the cannabis industry that can reduce energy costs by up to 82%. This represents a huge potential revenue stream for the company. Due to this fact the company has stated that marketing to cannabis companies is one of their top initiatives for 2019.
NEW YORK, April 18, 2019 /CNW/ -- The tremendous growth of the cannabis market is causing the marketspace to become an emerging global industry. Under international regulations, cannabis is one of the most heavily enforced drugs, primarily due to the psychoactive effects of marijuana. The marijuana plant is comprised primarily of THC, which causes the psychoactive effects.
One industry that is often overlooked but could play a huge role in the cannabis industry is energy. The U.S. cannabis industry is currently eating up more than 1% of all electricity each year. The need to reduce greenhouse emissions created by the weed industry, as well as lower electric load and expenditures, makes the energy sector a clear beneficiary of a budding cannabis industry.
DENVER, April 17, 2019 /CNW/ -- Ever since the Farm Bill was signed into law, farmers across the United States have rushed into hemp cultivation, driving demand for the supplies needed to grow the crop necessary to meet surging CBD use. Global hemp industry to reach $22 billion in 2022. Hemp is booming across the country, and nowhere more so than in Kentucky, where the applications to grow hemp are expected to increase fivefold, and acreage dedicated to growing the crop is set to more than triple this year.
NEW YORK, April 15, 2019 /CNW/ -- Canada moved to legalize cannabis entirely in late 2018, however, cannabis-based companies remain more attracted to the U.S. market. Despite not having legalized cannabis entirely, the U.S. market is one of the most attractive marketplaces for cannabis companies and investors. Many of these Canadian-based cannabis companies are beginning to establish operations in the U.S., particularly in large markets such as California, Colorado, and Nevada.
DENVER, April 11, 2019 /CNW/ -- The CBD market is experiencing explosive growth as a result of growing mainstream acceptance and strong leadership. The North American CBD market, worth more than $9 billion in 2017, is projected to be worth $47 billion by 2027. Growth is possible partly through mainstream acceptance, with pressure on a variety of institutions to accept medical CBD.
HENDERSON, NV / ACCESSWIRE / April 10, 2019 / Several Canada-based marijuana growers could be impacted by a build-up of un-sellable "sub-par quality" cannabis, as well as a slower rollout of ...
In October 2018, Canada became the second country to ever legalize cannabis entirely, joining Uruguay on that short list. Meanwhile, globally, a string of countries such as Australia, Germany, and South Korea began accelerating their medical cannabis programs.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), will announce its financial results for the first quarter ended March 31, 2019, and hold its First Quarter 2019 Earnings Conference Call on Thursday, May 9, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.
Many pieces of research have linked cannabis to effectively treating certain medical conditions such as cancer, chronic pain, epilepsy, and multiple sclerosis. THC is the psychoactive derivative of the marijuana family, which falls under the cannabis plant. On the other hand, CBD falls under the hemp family, which is also derived from cannabis.
CORAL GABLES, FL / ACCESSWIRE / April 4, 2019 / When speaking about the marijuana stock market, one cannot help but bring into the conversation the importance of companies with ancillary functions in the cannabis sector. ParcelPal Technology Inc (PTNYF) (PKG), Innovative Industrial Properties Inc (IIPR), Charlotte's Web Holding Corp (CWBHF), and Cronos Group Inc (NASDAQ: CRON, TSX: CRON) are 4 pot stocks heating things up on Thursday. ParcelPal Technology Inc (PTNYF) (PKG) today announced that the Company will be hosting an investor update conference call on May 17th, 2019 for the purpose of reviewing the Company's recent progress as well as provide investors with plans for the future.
Increased production driving high demand for hydroponic supplies. Hydroponics companies are responding with expansion and acquisitions. Sugarmade Inc. (OTC:SGMD - News) (SGMD Profile) has strategically acquired several companies to meet demand and expand its foothold.
The illicit cannabis industry is estimated at $50 billion yearly, much of which will move out of the shadows and become a legal market in the coming years. One research firm estimates the legal trade could be worth $21 billion by 2021. Item 9 Labs (INLB) could be one of these as they finish a major expansion project on their Arizona cannabis cultivation and production facility, doubling capacity.
Cannabis is still internationally illegal under regulatory statutes, but clinical trials and research have led countries to explore opportunities within the medical cannabis market. Unlike marijuana, hemp's main component is CBD. While THC provides psychoactive effects to consumers, CBD does not induce psychoactive effects, but provide a therapeutic and relaxing effect akin to that of THC.
Cannabis retail has rapidly emerged as one of the most important components of the marijuana value chain. Not only do retail gatekeepers control one of the most intimate parts of the cannabis purchasing experience, but they do so at a premium — making cannabis retail a likely determinant of any marijuana company’s staying power. In this article, we explore some of the leading cannabis retail brands in Canada.